Tags

Type your tag names separated by a space and hit enter

Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure.
Arch Intern Med. 2007 Jul 23; 167(14):1510-7.AI

Abstract

BACKGROUND

High adiponectin levels have been associated with reduced cardiovascular risk but have been shown to predict mortality in those at high risk for vascular disease. We examined the relationship between adiponectin levels and mortality in older men with and without diagnosed cardiovascular disease (CVD) and heart failure.

METHODS

Prospective study of 4046 men aged 60 to 79 years drawn from general practices in 24 British towns and followed up for a mean of 6 years, during which 734 deaths occurred. The men were divided into the following groups according to the presence of physician-diagnosed CVD and heart failure: (1) those with no CVD or heart failure; (2) those with CVD but without heart failure; and (3) those with heart failure (with or without CVD).

RESULTS

After adjustment for a wide range of baseline characteristics, adiponectin levels were positively associated with significantly increased all-cause and CVD mortality in men with no diagnosed CVD or heart failure (top third vs bottom third adjusted relative risk, 1.55 [95% confidence interval (CI), 1.19-2.02; P = .002 for trend] vs 1.53 [95% CI, 1.03-2.27; P = .02 for trend]), as well as in men with diagnosed heart failure ([adjusted relative risk, 2.37 [95% CI, 0.64-8.79; P = .04 for trend] vs 3.43 [95% CI, 0.54-21.70; P = .008 for trend]). No association was seen in those with diagnosed CVD without heart failure. Adjustment for weight loss and renal function made minor differences to these relationships.

CONCLUSIONS

In older men, high adiponectin levels are associated with increased all-cause and CVD mortality in those with heart failure and those free of CVD. Such observations suggest that adiponectin levels may reflect a balance of both protective and harmful factors.

Authors+Show Affiliations

Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, England. goya@pcps.ucl.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17646605

Citation

Wannamethee, S Goya, et al. "Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure." Archives of Internal Medicine, vol. 167, no. 14, 2007, pp. 1510-7.
Wannamethee SG, Whincup PH, Lennon L, et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007;167(14):1510-7.
Wannamethee, S. G., Whincup, P. H., Lennon, L., & Sattar, N. (2007). Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Archives of Internal Medicine, 167(14), 1510-7.
Wannamethee SG, et al. Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure. Arch Intern Med. 2007 Jul 23;167(14):1510-7. PubMed PMID: 17646605.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. AU - Wannamethee,S Goya, AU - Whincup,Peter H, AU - Lennon,Lucy, AU - Sattar,Naveed, PY - 2007/7/25/pubmed PY - 2007/8/29/medline PY - 2007/7/25/entrez SP - 1510 EP - 7 JF - Archives of internal medicine JO - Arch. Intern. Med. VL - 167 IS - 14 N2 - BACKGROUND: High adiponectin levels have been associated with reduced cardiovascular risk but have been shown to predict mortality in those at high risk for vascular disease. We examined the relationship between adiponectin levels and mortality in older men with and without diagnosed cardiovascular disease (CVD) and heart failure. METHODS: Prospective study of 4046 men aged 60 to 79 years drawn from general practices in 24 British towns and followed up for a mean of 6 years, during which 734 deaths occurred. The men were divided into the following groups according to the presence of physician-diagnosed CVD and heart failure: (1) those with no CVD or heart failure; (2) those with CVD but without heart failure; and (3) those with heart failure (with or without CVD). RESULTS: After adjustment for a wide range of baseline characteristics, adiponectin levels were positively associated with significantly increased all-cause and CVD mortality in men with no diagnosed CVD or heart failure (top third vs bottom third adjusted relative risk, 1.55 [95% confidence interval (CI), 1.19-2.02; P = .002 for trend] vs 1.53 [95% CI, 1.03-2.27; P = .02 for trend]), as well as in men with diagnosed heart failure ([adjusted relative risk, 2.37 [95% CI, 0.64-8.79; P = .04 for trend] vs 3.43 [95% CI, 0.54-21.70; P = .008 for trend]). No association was seen in those with diagnosed CVD without heart failure. Adjustment for weight loss and renal function made minor differences to these relationships. CONCLUSIONS: In older men, high adiponectin levels are associated with increased all-cause and CVD mortality in those with heart failure and those free of CVD. Such observations suggest that adiponectin levels may reflect a balance of both protective and harmful factors. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/17646605/Circulating_adiponectin_levels_and_mortality_in_elderly_men_with_and_without_cardiovascular_disease_and_heart_failure_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/archinte.167.14.1510 DB - PRIME DP - Unbound Medicine ER -